Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe


  Bladder Cancer

  Free Subscription


18.05.2020

1 Aging (Albany NY)
1 Aging Male
1 Am J Transplant
1 Biosci Rep
1 Cancer Biomark
1 Cancer Biother Radiopharm
1 Cancer Cell Int
2 Cancers (Basel)
1 Cell Death Dis
2 Cent European J Urol
1 Clin Lab
1 Curr Urol
1 Curr Urol Rep
1 Int J Cancer
1 Int J Mol Sci
1 J Natl Cancer Inst Monogr
1 J Oncol
1 J Palliat Care
4 J Urol
1 Mol Biol Rep
1 Mol Oncol
1 Nat Biomed Eng
1 Oncogenesis
1 Technol Cancer Res Treat
1 Toxicol In Vitro
2 Urol Oncol
1 Wiad Lek
1 Zhongguo Yi Xue Ke Xue Yuan Xue Bao


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aging (Albany NY)

  1. TAN L, Xiao K, Ye Y, Liang H, et al
    High PRMT5 expression is associated with poor overall survival and tumor progression in bladder cancer.
    Aging (Albany NY). 2020;12.
    PubMed         Abstract available


    Aging Male

  2. KUTLUHAN MA, Ozsoy E, Baskak F, Urkmez A, et al
    How reliable are imaging techniques in aging males with bladder cancer?
    Aging Male. 2020 May 13:1-7. doi: 10.1080/13685538.2020.1766014.
    PubMed         Abstract available


    Am J Transplant

  3. LUO HL, Chen YT, Cheng YT
    Reply to: High-grade urothelial carcinoma in a kidney transplant recipient after JC virus nephropathy: The first evidence of JC virus as a potential oncovirus in bladder cancer.
    Am J Transplant. 2020 May 14. doi: 10.1111/ajt.16006.
    PubMed         Abstract available


    Biosci Rep


  4. Correction: High LINC01605 expression predicts poor prognosis and promotes tumor progression via upregulation of MMP9 in bladder cancer.
    Biosci Rep. 2020;40.
    PubMed        


    Cancer Biomark

  5. CAO H, Cheng L, Yu J, Zhang Z, et al
    Identifying the mRNAs associated with Bladder cancer recurrence.
    Cancer Biomark. 2020 Apr 30. pii: CBM190617. doi: 10.3233/CBM-190617.
    PubMed         Abstract available


    Cancer Biother Radiopharm

  6. CHEN D, Chen J, Gao J, Zhang Y, et al
    LncRNA DDX11-AS1 Promotes Bladder Cancer Occurrence Via Protecting LAMB3 from Downregulation by Sponging miR-2355-5p.
    Cancer Biother Radiopharm. 2020 May 15. doi: 10.1089/cbr.2019.3021.
    PubMed         Abstract available


    Cancer Cell Int

  7. CHEN Q, Yin Q, Mao Y, Zhang Z, et al
    Hsa_circ_0068307 mediates bladder cancer stem cell-like properties via miR-147/c-Myc axis regulation.
    Cancer Cell Int. 2020;20:151.
    PubMed         Abstract available


    Cancers (Basel)

  8. WOLACEWICZ M, Hrynkiewicz R, Grywalska E, Suchojad T, et al
    Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives.
    Cancers (Basel). 2020;12.
    PubMed         Abstract available

  9. LIU YC, Chen VC, Lu ML, Lee MJ, et al
    The Association between Selective Serotonin Reuptake Inhibitors (SSRIs) Use and the Risk of Bladder Cancer: A Nationwide Population-Based Cohort Study.
    Cancers (Basel). 2020;12.
    PubMed         Abstract available


    Cell Death Dis

  10. XIONG Q, Liu A, Ren Q, Xue Y, et al
    Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer.
    Cell Death Dis. 2020;11:366.
    PubMed         Abstract available


    Cent European J Urol

  11. ZHEGALIK AG, Polyakov SL, Rolevich AI, Volkov AN, et al
    Long-term results of a single-center prospective randomized trial assessing efficacy of a shortened course of adjuvant chemotherapy after radical cystectomy in patients with locally advanced bladder cancer.
    Cent European J Urol. 2020;73:26-32.
    PubMed         Abstract available

  12. GRONOSTAJ K, Czech AK, Fronczek J, Wiatr T, et al
    Changes in neoadjuvant chemotherapy utilization in muscle invasive bladder cancer treatment: a tertiary center retrospective study.
    Cent European J Urol. 2020;73:13-18.
    PubMed         Abstract available


    Clin Lab

  13. GUAN H, Li X, Lu J, Meng L, et al
    Aberrant Methylation of Suppressor of Cytokine Signaling 1 (SOCS1) Gene as a Biomarker for Early Prediction and Diagnosis of Bladder Cancer.
    Clin Lab. 2020;66.
    PubMed         Abstract available


    Curr Urol

  14. VOSKAMP MJH, Vermeer M, Molijn GJ, Cornel EB, et al
    The Usefulness of the Modified Frailty Index for Muscle-Invasive Bladder Cancer Patients Treated with Radical Cystectomy.
    Curr Urol. 2020;14:32-37.
    PubMed         Abstract available


    Curr Urol Rep

  15. JALANKO T, de Jong JJ, Gibb EA, Seiler R, et al
    Correction to: Genomic Subtyping in Bladder Cancer.
    Curr Urol Rep. 2020;21:25.
    PubMed         Abstract available


    Int J Cancer

  16. LI Y, Hendryx MS, Xun P, He K, et al
    Physical activity and risk of bladder cancer among postmenopausal women.
    Int J Cancer. 2020 May 10. doi: 10.1002/ijc.33042.
    PubMed         Abstract available


    Int J Mol Sci

  17. MATUSZCZAK M, Salagierski M
    Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers.
    Int J Mol Sci. 2020;21.
    PubMed         Abstract available


    J Natl Cancer Inst Monogr

  18. LAM CJK, Warren JL, Nielsen M, Smith A, et al
    Using the SEER-Medicare Data to Assess Incident Chronic Myeloid Leukemia and Bladder Cancer Cases Missed by Cancer Registries.
    J Natl Cancer Inst Monogr. 2020;2020:31-38.
    PubMed         Abstract available


    J Oncol

  19. LUO C, Lei T, Zhao M, Meng Q, et al
    CD40 is Positively Correlated with the Expression of Nucleophosmin in Cisplatin-Resistant Bladder Cancer.
    J Oncol. 2020;2020:3676751.
    PubMed         Abstract available


    J Palliat Care

  20. HAN H, Yu F, Wu C, Dai L, et al
    Trends and Utilization of Inpatient Palliative Care Among Patients With Metastatic Bladder Cancer.
    J Palliat Care. 2020 May 14:825859720924936. doi: 10.1177/0825859720924936.
    PubMed         Abstract available


    J Urol

  21. CHANG SS
    Re: Association between Treatment of Superficial Bladder Cancer and 10-Year Mortality in Older Adults with Multiple Chronic Conditions.
    J Urol. 2020 May 12:101097JU000000000000111401.
    PubMed        

  22. GRIEBLING TL
    Re: Rate and Determinants of Completing Neoadjuvant Chemotherapy in Medicare Beneficiaries with Bladder Cancer: A SEER-Medicare Analysis.
    J Urol. 2020 May 13:101097JU000000000000110204.
    PubMed        

  23. CHANG SS
    Re: Assessment of Quality of Life, Information, and Supportive Care Needs in Patients with Muscle and Non-Muscle Invasive Bladder Cancer across the Illness Trajectory.
    J Urol. 2020 May 12:101097JU000000000000111402.
    PubMed         Abstract available

  24. ATALA A
    Re: A Genetically Defined Disease Model Reveals that Urothelial Cells Can Initiate Divergent Bladder Cancer Phenotypes.
    J Urol. 2020 May 12:101097JU0000000000001117. doi: 10.1097/JU.0000000000001117.
    PubMed        


    Mol Biol Rep

  25. WU T, Duan X, Hu T, Mu X, et al
    Effect of endostatin on Wnt pathway of stem-like cells in bladder cancer in tumor microenvironment.
    Mol Biol Rep. 2020 May 9. pii: 10.1007/s11033-020-05487.
    PubMed         Abstract available


    Mol Oncol

  26. YOSHINO H, Enokida H, Osako Y, Nohata N, et al
    Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation.
    Mol Oncol. 2020 May 9. doi: 10.1002/1878-0261.12697.
    PubMed         Abstract available


    Nat Biomed Eng

  27. HAEDICKE K, Agemy L, Omar M, Berezhnoi A, et al
    High-resolution optoacoustic imaging of tissue responses to vascular-targeted therapies.
    Nat Biomed Eng. 2020;4:286-297.
    PubMed         Abstract available


    Oncogenesis

  28. ZHANG J, Duan H, Feng Z, Han X, et al
    Acetyl-CoA synthetase 3 promotes bladder cancer cell growth under metabolic stress.
    Oncogenesis. 2020;9:46.
    PubMed         Abstract available


    Technol Cancer Res Treat

  29. MA J, Qi J, Li S, Zhang C, et al
    Desloratadine, a Novel Antigrowth Reagent for Bladder Cancer.
    Technol Cancer Res Treat. 2020;19:1533033820926591.
    PubMed         Abstract available


    Toxicol In Vitro

  30. QI Y, Toyooka T, Nie J, Ohta H, et al
    Comparative gamma-H2AX analysis for assessment of the genotoxicity of six aromatic amines implicated in bladder cancer in human urothelial cell line.
    Toxicol In Vitro. 2020;66:104880.
    PubMed         Abstract available


    Urol Oncol

  31. GARG T, Young AJ, O'Keeffe-Rosetti M, McMullen CK, et al
    Association between metabolic syndrome and recurrence of nonmuscle-invasive bladder cancer in older adults.
    Urol Oncol. 2020 May 11. pii: S1078-1439(20)30150.
    PubMed         Abstract available

  32. SHARMA M, Nagata Y, Yang Z, Miyamoto H, et al
    The impact of routine frozen section analysis during partial cystectomy for bladder cancer on surgical margin status and long-term oncologic outcome.
    Urol Oncol. 2020 May 8. pii: S1078-1439(20)30140.
    PubMed         Abstract available


    Wiad Lek

  33. STAKHOVSKYI OE, Pikul MV, Semko SL, Vitruk IV, et al
    Transperitoneal uretercutaneostomy with use of mesosigmoid colon peritoneum in patients with bladder cancer after radical cystectomy.
    Wiad Lek. 2020;73:988-993.
    PubMed         Abstract available


    Zhongguo Yi Xue Ke Xue Yuan Xue Bao

  34. WANG F, Qin CP, Yang WB, Liu SJ, et al
    [Advances in Pelvic Lymph Node Dissection for Bladder Cancer].
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2020;42:263-269.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: